Trial Profile

A clinical study of tropifexor in combination of one or more Pfizer compounds for the treatment of NASH

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 21 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Clesacostat (Primary) ; Ervogastat (Primary) ; PF 06835919 (Primary) ; Tropifexor (Primary)
Indications Non-alcoholic steatohepatitis
Focus Therapeutic Use

Most Recent Events

09 Jan 2026 According to Madrigal Pharmaceuticals media release, company plan to consult with the FDA on design of a Phase 2 combination trial.
05 Nov 2018 New trial record
29 Oct 2018 According to a Novartis media release, the company went under the agreement with Pfizer to initiate this combination study with Pfizer drugs.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com